Conjugate including a severable linker

JP2026514774A5Pending Publication Date: 2026-07-01ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025560296
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-18
Filing Date
2024-04-09
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

There is a need for antibody drug conjugates (ADCs) with β-glucuronidase-cleavable linkers that can selectively deliver drugs to biological targets while maintaining desirable physicochemical properties such as solubility and lipophilicity, particularly for the treatment of diseases like cancer.

Method used

Conjugates containing linkers of specific formulas (I), (IC), (IM), or (IT) with defined structures and connections, which allow for enzymatic cleavage and improved stability, solubility, and reduced toxicity, suitable for cancer treatment.

Benefits of technology

The conjugates exhibit enhanced efficacy and favorable properties, including higher stability, solubility, and reduced toxicity, making them particularly suitable for cancer therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

This specification relates to conjugates containing a linker of formula (IA) and pharmaceutically acceptable salts thereof. This specification also relates to the use of conjugates for the treatment of diseases such as cancer and intermediates useful for the synthesis of conjugates. [Formula 1] JPEG2026514774000204.jpg30128
Need to check novelty before this filing date? Find Prior Art